In December, the FDA accepted Savient Pharmaceuticals, Inc. Biologics License Application (BLA) for pegloticase. Pegloticase, formerly known as Puricase(R), is a biological drug for the treatment of gout which has not responded to the currently available medications (treatment-failure gout). Patients with treatment-failure gout tend to have severe pain at the affected joint and limited function. Continue Reading »